Evaluation of Anti-Mutated Citrullinated Vimentin Antibodies, Anti-Cyclic Citrullinated Peptide Antibodies and Rheumatoid Factor in Omani Patients with Rheumatoid Arthritis

Table 1

Demographic information and laboratory investigations of Rheumatoid Arthritis (RA) patients and control groups.

Variables	RA patients	Healthy control	𝑃 value
	𝑁=80	𝑁=133
Age (year, mean ± SD)	41.6±14.5	35±7	0.875
Sex (%)
Female	71 (87.5)	70 (52.6)	0.983
Male	9 (12.5)	63 (47.4)
Smoking status (%)
Yes	1 (1.2)	2 (1.5)	0.28
No	79 (99)	131 (98.5)
Disease duration; (year, mean ± SD)	10.3±18.7	NA
ESR median; (interquartile range)	23 (28)	NA
CRP median; (interquartile range)	8 (16)	NA
Positive (%)
Anti-MCV (>20 U/mL)	58 (72.5)	16 (12)	<0.0001
Anti-CCP (>5 RU/mL)	49 (61)	3 (2.3)	<0.0001
RF (>30 U/mL)	47 (59)	7 (5)	<0.0001

NA: not available, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, MCV: mutated citrullinated vimentin, CCP: cyclic citrullinated peptide, and RF: rheumatoid factor.